Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: A meta-analysis of randomized controlled trials

Chinese Medicine

Volumn 1, Issue , 2006, Pages

  Liu, Jianping ^a,c   Zhang, Jing ^b   Shi, Yi ^b   Grimsgaard, Sameline ^a   Alraek, Terje ^a   Fønnebø, Vinjar ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34250741897     PISSN: None     EISSN: 17498546     Source Type: Journal    
DOI: 10.1186/1749-8546-1-4     Document Type: Review

References (113)

1. Monascus purpureus (monograph) Altern Med Rev 2004 9 2 208-210 15253679
2. Ma J Li Y Ye Q Li J Hua Y Ju D Zhang D Cooper R Chang M Constituents of red yeast rice, a traditional Chinese food and medicine J Agric Food Chem 2000 48 11 5220-5 10.1021/jf000338c 11087463
3. Patrick L Uzick M Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature Altern Med Rev 2001 6 3 248-71 11410071
4. Heber D Lembertas A Lu QY Bowerman S Go VL An analysis of nine proprietary Chinese red yeast rice dietary supplements: Implications of variability in chemical profile and contents J Altern Complement Med 2001 7 2 133-9 10.1089/107555301750164181 11327519
5. Wang J Lu Z Chi J Wang W Su M Kou W Yu P Yu L Chen L Zhu JS Chang J Multicenter clinical trial of the serum lipid-lowering effects of a Monascus purpureus (red yeast) rice preparation from traditional Chinese medicine Cur Ther Res 1997 58 964-978 10.1016/S0011-393X(97)80063-X
6. Kou WR Lu ZL Guo JX Li HY Xue SW Lin YZ Wu XS Chen H Effect of Xuezhikang on the treatment of primary hyperlipidemia Zhonghua Neike Zazhi 1997 36 8 529-31 10436958
7. Heber D Yip I Ashley JM Elashoff DA Elashoff RM Go VL Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement Am J Chin Nutr 1999 69 2 231-6
8. Shen ZW Yu PL Sun MZ Chi JM Zhou YF Zhu XS Yang CY He CF Prospective study of Xuezhikang for treatment of primary hyperlipidemia Natl Med J China 1996 76 2 156-7
9. Liu SS Kou MK Ding H Li CM He L He L Zhang CM Li YF Li ZF Yang MJ The clinical observation of hyperlipoproteinemia treated with Zhibituo Chengdu Zhongyiyao Daxue Xuebao 1996 19 3 12-5
10. Kreisberg RA Oberman A Medical management of hyperlipidemia/dyslipidemia J Clin Endocrinol Metab 2003 88 6 2445-61 10.1210/jc.2003-030388 12788840
11. Moghadasian MH A safety look at currently available statins Expert Opin Drug Saf 2002 1 3 269-74 10.1517/14740338.1.3.269 12904142
12. Alcocer L Statins for everybody? New evidence on the efficacy and safety of the inhibitors of HMG Co-A reductase Am J Ther 2003 10 6 423-8 10.1097/00045391-200311000-00008 14624280
13. Bellosta S Paoletti R Corsini A Safety of statins: Focus on clinical pharmacokinetics and drug interactions Circulation 2004 109 11150-7 10.1161/01.CIR.0000131519.15067.1f
14. Thompson Coon JS Ernst E Herbs for serum cholesterol reduction: A systematic review J Fam Pract 2003 52 6 468-78 12791229
15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 2001 285 19 2486-97 10.1001/jama.285.19.2486 11368702
16. Schulz KF Chalmers I Hayes R Altman D Empirical evidence of bias JAMA 1995 273 5 408-12 10.1001/jama.273.5.408 7823387
17. Moher D Pham B Jones A Cook DJ Jadad AR Moher M Tugwell P Klassen TP Does quality of reports of randomized trials affect estimates of intervention efficacy reported in meta-analyses Lancet 1998 352 9128 609-13 10.1016/S0140-6736(98)01085-X 9746022
18. Kjaergard LL Villumsen J Gluud C Reported methodological quality and discrepancies between large and small randomized trials in meta-analyses Ann Intern Med 2001 135 11 982-9 11730399
19. Clarke M Oxman AD Assessment of study quality. Cochrane Reviewers' Handbook 4.2.0 [updated March 2003] The Cochrane Library Oxford: Update Software 2003 2
20. Higgins JPT Thompson SG Deeks JJ Altman DG Measuring inconsistency in meta-analyses BMJ 2003 327 7414 557-60 192859 12958120 10.1136/ bmj.327.7414.557
21. Personal communication with the trial sponsors in Norway and Italy
22. Tang HL Randomized controlled study of Diao Zhibituo for lipid modulation effect Sichuan Yixue 2004 25 1 78-9
23. Zhao YL Ouyang HB Observation on therapeutic effects of Zhibituo for treatment of hyperlipidemia Changchun Yixue Zazhi 1998 11 1 21
24. Cheng XM Yu ZM Luo HD Qiu YH Chen MX Effect of Xuezhikang on endothelial function in patients with hyperlipidemia Chin J Arterioscler 2001 9 3 235-7
25. Qin SC Zhang WQ Qi P Zhao ML Dong ZN Li YC Xu XM Fang X Fu L Randomized, double blind, controlled trial for the clinical therapeutic effects of Xuezhikang in the elderly with hyperlipidemia Zhonghua Neike Zazhi 1998 37 6 401-2
26. Xiao M Ye P Clinical observation of Xuezhikang for treatment of hyperlipidemia Shuli Yixue Zazhi 2001 14 3 244-5
27. Huang GZ Yang S Wu ZG Observation on therapuetic effect of Zhibituo for treatment of hyperlipidemia Dier Junyi Daxue Xuebao 1998 19 1 94-5
28. Peng DY Observation on the effect of Zhibituo in treating hyperlipidemia Zhongguo Yejin Gongye Yixue Zazhi 1998 15 4 201-3
29. Xu JM Chen SX Hu WY Cai NS Xu Q Wu ZG Sun KX Zhibituo vs. placebo treatment of hyperlipidemia a double blind randomized and multicenter study Zhongguo Xinyao Yu Linchuang Zazhi 1997 16 1 47-51
30. Chen FJ Ruan Q Qi HW Yuan PY Clinical observation of Xuezhikang in treating middle and old age hyperlipidemia Shanghai Yufangyixue Zazhi 2003 15 5 222-3
31. Chen LL Liu J Effects of Xuezhikang on hypercholesterolemia Yiyao Daobao 2002 21 1 31-2
32. Li QL Zhang YF Clinical observation on effect of Taizhi'an capsule in treating 150 patients with hyperlipidemia Zhongguo Zhongxiyi Jiehe Zazhi 2003 23 5 335-7 12800412
33. Lu GP Huo SQ Shen YC Gong LS Comparison of the effects of Xuezhikang with simvastatin on lipid profile modification in patients with hypercholesterolemia Zhonghua Neike Zazhi 1998 37 6 371-3
34. Quan SL Wang W Qu XW Chen J Controlled observation on therapeutic effects of Xuezhikang and simvastatin for treatment of hypercholesterolemia Zhonghua Shiyong Yixue 2003 3 5 427
35. Shen G Wang J Wang JF Comparison of the effects of the herbal lipid regulator decoction, Xuezhikang and simvastatin on lipid modulation in the middle-aged and elderly subjects with hyperlipidemia Zhongguo Jiceng Yiyao 2000 7 4 280-1
36. Wang SH Sun JL Liu HQ Therapeutic observations of Xuezhikang for treatment of 60 cases of elderly with hyperlipidemia Anhui Linchuang Zhongyi Zazhi 2003 15 6 474-5
37. Wang XL Hu XM Comparison of Xuezhikang and simvastatin in regulating lipids for hypercholesterolemia Zhongxiyi Jiehe Xinnaoxueguanbing Zazhi 2004 2 6 319-20
38. Xi BL Ren JY Effects of Xuezhikang vs. simvastatin in treating hyperlipidemia Guowai Yixue: Xin Xueguanbing Fence 2002 29 4 233-4
39. Zeng TK Observation of the therapeutic effects of Xuezhikang for treatment of 77 elderly with hyperlipidemia Shoudu Yiyao 1999 6 11 49
40. Zhang G Zhang KX Xu Z Guang XF Comparison of lipid-lowering effects of Xuezhikang and Simvastatin for hyperlipidemia Shoudu Yiyao 1998 5 6 35-6
41. Zhao XH Jiang XM Ao LJ Therapeutic observations of Xuezhikang for treatment of hyperlipidemia Yunnan Yiyao 1998 19 1 26
42. Zheng Y Luo XZ Wang SL Yang YJ Clinical controlled study on the therapeutic effects of Xuezhikang and Simvastatin Zhongguo Yaoshi 2001 36 10 715
43. Zhu QF Jiang L Wang Y Effects of Xuezhikang and simvastatin on apolipoprotein B and A1 in patients with hyperlipidemia Guangming Zhongyi 2003 18 5 24-5
44. Chen L Qin YW Guo RB Clinical efficacy of capsule Xuezhikang in treatment of hypercholesterolemia Yaoxue Fuwu Yu Yanjiu 2002 2 1 39-40
45. Jin W Yang H Zhang C Zhang CJ Xu YH Therapeutic observations of Xuezhikang for treatment of primary hyperlipidemia Zhongguo Zhongxiyi Jiehe Zazhi 1997 17 7 434-5
46. Lei HZ Effects of Xuezhikang on endothelial function in aged patients with hyperlipidemia Guangxi Yixue 2004 26 4 495-7
47. Li YS Lei HZ Zhu MJ Clinical observations of 41 cases of elderly with hyperlipidemia treated with Xuezhikang Zhongguo Quanke Yixue 2003 6 2 163
48. Wang DG Li D Nie ZY Application of cost-effectiveness analysis in Xuezhikang and pravastatin for the treatment hypercholesterolemia Zhongguo Yaoshi 2003 12 9 53-5
49. Xu CB Hu DY Kang LP Tian YW Gao MM Xu ZM Jin SY Ma FY Ma M Shi XY Zhang BH Long NZ Li L Xue L Zhang JH Chen XL Dai CX Comparative study of relatively long-term therapy for dyslipidemia with low-dose Xuezhikang or pravastatin in Chinese patients Zhongguo Yaoxue 2000 9 4 218-22
50. Yu CY Zhang C Yang H Jin W Observations of therapeutic effects of Xuezhikang for treatment of primary hyperlipidemia Heilongjiang Yixue Zazhi 2004 17 2 151-2
51. Li BH Zheng GJ Zhang WG Xu M Ren P Clinical observations of Ruanmaijianzhi capsule in the treatment of dyslipidemia Hebei Zhongyi Zazhi 2004 26 9 657-9
52. Xu SG Analysis of therapeutic effect of Xuezhikang for treatment of primary hypercholesterolemia Henon Yixue Xinxi 2002 10 13 6-7
53. Zheng FS Long XD Liu HM Liu YL Bao YZ Yu M Comparison of lovastatin and Chinese Xuezhikang in lipid modification for primary hyperlipidemia Yunan Yixue 2000 21 5 442-3
54. Shen MY Comparison of the effects of Xuezhikang and atorvastatin for treatment of hyperlipidemia Zhonghua Shiyong Yiyao Zazhi 2003 2 5 439-40
55. Wang AH Zhang GD Comparison of the therapeutic effects of Xuezhikang and Lescol for treatment of hyperlipidemia Zhongguo Zonghe Yixue 2002 3 7 617-8
56. Chen ZM Comparison of the therapeutic effects of simvastatin and Zhibituo for treatment of hyperlipidemia Guangxi Yike Daxue Xuebao 2001 18 4 543
57. Guo WC Feng WJ Clinical observations of statin alone or combined with unsaturated fatty acids for the treatment of combined hyperlipidemia in elderly people Beijing Yixue 2003 25 1 25-7
58. Guo XM Tu L Mi S Comparison of the therapeutic effects of Zhibituo and simvastatin for regulating dyslipidemia Zhongyao Yaoli Yu Linchuang 1999 15 6 46-8
59. Huang YL Zhou JG Zhang HF Shi YX Wang MS Comparison of the therapeutic effects of simvastatin and Zhibituo for the elderly with hyperlipidemia Yixue Yu Gongcheng 2001 3 1 24-7
60. Yang WJ Fu XJ Comparison of the therapeutic effects of Zhibituo and simvastatin for treatment of hyperlipidemia Zhongguo Xiandai Yiyao Yu Jishu 2003 3 2 2-4
61. Zhang GR Comparison of Zhibituo and simvastatin for their effects on hyperlipidemia Guangxi Yixue 2002 24 5 713-4
62. Zhang QL Comparative interventional therapies of dyslipidemia by simvastatin and Zhibituo with 60 cases Guoji Yiyao Weisheng Daobao 2004 10 10 29-30
63. Zheng CJ Wang P Zhibituo vs. simvastatin in treatment of hyperlipidemia Zhongguo Yaoshi 2001 4 6 447-8
64. Wang SX Comparison of the therapeutic effects of Xuezhikang and lovastatin Xiandai Zhongxiyi Jiehe Zazhi 2004 13 20 2707
65. Li DX Li YF Lu HY Comparison of the effects of Xuezhikang with inositol hexanicotinate on lipid profile modification Henan Zhigong Yixueyuan Xuebao 2000 12 1 17-8
66. Li YM Sun RX Therapeutic observations on Xuezhikang for treatment of hyperlipidemia Zhongguo Shiyong Xiangcun Yisheng Zazhi 2004 11 8 25-6
67. Liu L Li JP Shen PN Clinical observations of Xuezhikang for treatment of mixed type of hyperlipidemia Zhonghua Shiyong Yixue 2000 16 12 1047-8
68. Qi P Huang Y Deng J Effects of Xuezhikang vs. Inositol niacinate in treating hyperlipidemia Jiangxi Yixueyuan Xuebao 2002 42 4 24-5
69. Yang SS Xuezhikang for treatment of 76 patients with hyperlipidemia Zhongchengyao 2002 24 10 815-6
70. Zhang JS Comparison of Xuezhikang and inositol nicotinate for treatment of hyperlipidemia Zhiye Yu Jiankang 2002 18 1 138-40
71. Zheng JR Wang B Effects of Xuezhikang on treatment of primary hyperlipidemia Yixue Luntan Zazhi 2004 25 14 21-2
72. Zhou ZL Liu CH Xuezhikang for treatment of 20 cases of hyperlipidemia Hunan Zhongyiyao Daobao 1999 5 7 25
73. Jiang HP Comparison of the therapeutic effects and compliance of Xuezhikang anFenofibrate in patients with hyperlipidemia Xiandai Zhenduan Yu Zhiliao 2001 12 Suppl 29
74. Li GR Li JP Mai WY Zeng Y Micronised fenofibrate for treatment of mixed type of hyperlipidemia Guangdong Yixue 1999 20 11 895-6
75. Ma F Ma XH Clinical observation of Finofibrate and Xuezhikang for treatment of hyperlipidemia Zhongguo Hangtianye Yiyao 2003 5 1 55-6
76. Zhu WM Wu SR Effects and safety of combined treatment by Xuezhikang and micronized fenofibrate in patients with hyperlipidemia Zhongguo Linchuang Yixue Zazhi 2003 4 2 18-20
77. Jiang JB Hao XY Deng CQ Zhou HT Lin J Effects of Xuezhikang on serum lipid profile, thromboxane A2 and prostacyclin in patients with hyperlipidemia Zhonghua Neike Zazhi 1999 38 8 517-9 11798687
78. Wang CW Gao FM You L Clinical study on the therapeutic effects of Xuezhikang for treatment of hyperlipidemia Mudanjiang Yixueyuan Xuebao 2000 21 3 13
79. Wang YF Yang CK Xu WJ Sun L Liu B Wang GG Xuezhikang, gemfibrozil for regulation of hyperlipidemia in elderly and insulin sensitivity Zhongguo Xinyao Zazhi 1998 7 3 209-11
80. Liu ZB Xuezhikang for treatment of 40 cases of hyperlipidemia Linchuang Huicui 1998 13 8 367-8
81. Xia CH Comparison of lipid modification of Xuezhikang and Duoxikang in hyperlipidemia Suzhou Yixueyuan Xuebao 1999 19 9 1015-6
82. Xu WY Yan YZ Tang ZH Therapeutic observations on Xuezhikang capsules for treatment of hyperlipidemia Haixia Yaoxue 2003 15 2 65-6
83. Zheng H Dan XY Ning H Xue B Observations of Xuezhikang on clinical effects and haemorheology Hebei Yiyao 2001 7 1 46-8
84. Zhang WM Yang JX Li F Zhang GW Observations of Xuezhikang in treatment of hyperlipidemia and abnormal haemorheology Henan Shiyong Shenjingbing Zazhi 2000 3 3 47-8
85. Feng JC Wang JS Wang CP Jiang YJ Tan GZ Effects of conjugated estrogen and Xuezhikang in low dosage on blood lipid in postmenopausal women Xiandai Zhongxiyi jiehe Zazhi 2000 9 23 2334-5
86. Kong YM Gao H Liu XL Clinical observations of the lipid-lowering effects of Xuezhikang and elastase Zhongguo Yaoshi 1999 8 3 56
87. Yan HD Guo JH Jia ST Observations of the short-term effects of Probucol in treatment of hyperlipidemia Shanxi Linchuang Yixue 1999 8 2 103-4
88. Bi JZ Ma SZ Li YQ Observations on the therapeutic effects of Diao Zhibituo for treatment of hyperlipidemia Shiyong Zhongxiyi jiehe Zazhi 1996 9 12 729
89. Cai MX Deng JX Lu LF Clinical observations on Diao Zhibituo for treatment of hyperlipidemia Fujian Yiyao Zazhi 1997 19 2 83-4
90. Cong B Observations on the therapeutic effects of Zhibituo for treatment of hyperlipidemia Hebei Yiyao 1999 5 3 60-1
91. Huang LJ Chen MS Comparison of Diao Zhibituo and Inositol nicotinate for the lipid lowering effects Zhongyuan Yikan 1997 24 1 8-10
92. Li FL Zeng WH Comparison of Zhibituo and Inositol nicotinate for treatment of hyperlipidemia Nongken Yixue 2002 24 3 198-9
93. Ma L Gao Y Li BZ Observations of the therapeutic effects of Zhibituo for treatment of 50 patients with hyperlipidemia Xibei Yaoxue Zazhi 2000 15 3 126
94. Qiu JP Wang ZJ Xu XP Ma SY Kuang RJ Observations of Zhibituo on the therapeutic effects in treatment of 60 patients with hyperlipidemia Shandong Yiyao 2002 42 6 45-6
95. Yang MJ Wang RZ Zhibituo for treatment of 100 cases of hyperlipidemia Zhongguo Xinyao Yu Linchuang Zazhi 1997 16 1 9-10
96. Yu HY Li TH Observations on the therapeutic effects of Zhibituo for treatment of hyperlipidemia Xinxueguan Kangfu Yixue Zazhi 1999 8 1 30-1
97. Chen GY Observations on the therapeutic effects of Zhibituo for treatment of hyperlipidemia in the elderly Guizhou Yiyao 1999 23 4 307-8
98. Chen JF Yan ZZ Li PT Comparison of Zhibituo and Duoxikang for treatment of hyperlipidemia Zhongguo Xinyao Yu Linchuang Zazhi 1997 16 1 15-17
99. Fu G Liu WJ Wang GT Comparison of Zhibituo and fish oil capsules for treatment of hyperlipidemia Heilongjiang Yiyao 2000 23 5 93-4
100. Jin WQ Li CW Xu M Gao YX Xu XW Comparison of Zhibituo and Duoxikang in treating 108 patients with hyperlipidemia Zhongguo Xinyao Yu Linchuang Zazhi 1997 16 1 61-2
101. Li Y Min YB Fan XJ Comparison of the therapeutic effects of Zhibituo and fish oils for treatment of 30 cases of hyperlipidemia Guangdong Yaoxue Zazhi 2000 10 1 43-5
102. Wang LB Qiao JJ Li YM Clinical evaluation of Zhibituo and concentrated fish oils for treatment of hyperlipidemia Jiamusi Yixueyuan Xuebao 1998 21 1 62-3
103. Yang Q Xue HQ Observations on the therapeutic effects of Zhibituo for treatment of hyperlipidemia Zhongguo Jiceng Yiyao 1999 6 3 129
104. Gu ZY Lu ZF Zhu HQ Observations on the therapeutic effects of Zhibituo for treatment of 158 patients with hyperlipidemia Nantong Yixueyuan Xuebao 1998 18 3 374-5
105. Chen ZL Controlled study of Diao Zhibituo and alginic sodium diester for lipid lowering effect Henan Shiyong Shenjingbing Zazhi 1998 1 2 20
106. Chen L Qin YW Zheng X Effects of lipid modification of Diao Zhibituo capsules Zhongguo Zhongxiyi Jiehe Zazhi 2003 23 5 389
107. Guo XL Li Y Yin GN Xuezhikang for treatment of 30 cases of hyperlipidemia Ningxia Yixue Zazhi 1999 21 7 418
108. Lu WX Wang JX Zhu JG Xu DS Yang MJ Wang HW Wang RZ Zheng R Zhibituo capsules in treatment of hyperlipidemia: A multi-centre clinical trial Zhongguo Xinyao Yu Linchuang Zazhi 1999 18 6 365-7
109. Lu YS Gu JS Zhou WG Comparison of the therapeutic effects of Xuezhikang and Zhibituo in treatment of adults with hyperlipidemia Zhongguo Zhongxiyi Jiehe Zazhi 1998 18 8 467
110. Sun FF Ding XF Wang M Comparison of lipid-lowering effects of Xuezhikang and Zhibituo Jiceng Yixue Luntan 2004 8 2 121-2
111. Xiao CL Yao ZQ He SM Comparison of the lipid modification effects of Xuezhikang and Zhibituo for hypercholesterolemia Guangdong Yixue Zazhi 2000 21 5 430-1
112. Vickers A Goyal N Harland R Rees R Do certain countries produce only positive results? A systematic review of controlled trials Contral Clin Trials 1998 19 2 159-66 10.1016/S0197-2456(97)00150-5
113. Graham DJ Staffa JA Shatin D Andrade SE Schech SD La Grenade L Gurwitz JH Chan KA Goodman MJ Platt R Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs JAMA 2004 292 21 2585-90 10.1001/jama.292.21.2585 15572716